176 related articles for article (PubMed ID: 18387274)
21. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
22. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
[TBL] [Abstract][Full Text] [Related]
23. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF.
Dörr W; Heider K; Spekl K
Int J Radiat Biol; 2005 Aug; 81(8):557-65. PubMed ID: 16298937
[TBL] [Abstract][Full Text] [Related]
24. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
[TBL] [Abstract][Full Text] [Related]
26. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation.
Dörr W; Reichel S; Spekl K
Radiother Oncol; 2005 Apr; 75(1):99-105. PubMed ID: 15878107
[TBL] [Abstract][Full Text] [Related]
27. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis.
Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
Anticancer Res; 2014 Dec; 34(12):7379-82. PubMed ID: 25503176
[TBL] [Abstract][Full Text] [Related]
28. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
[TBL] [Abstract][Full Text] [Related]
29. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
30. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT).
Stiff PJ; Erder H; Bensinger WI; Emmanouilides C; Gentile T; Isitt J; Lu ZJ; Spielberger R
Bone Marrow Transplant; 2006 Feb; 37(4):393-401. PubMed ID: 16415901
[TBL] [Abstract][Full Text] [Related]
31. Oral mucositis.
Scully C; Sonis S; Diz PD
Oral Dis; 2006 May; 12(3):229-41. PubMed ID: 16700732
[TBL] [Abstract][Full Text] [Related]
32. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
[TBL] [Abstract][Full Text] [Related]
33. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history.
Grzegorczyk-Jaźwińska A; Kozak I; Karakulska-Prystupiuk E; Rokicka M; Ganowicz E; Dwilewicz-Trojaczek J; Górska R
Adv Med Sci; 2006; 51 Suppl 1():66-8. PubMed ID: 17460832
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Safety Outcomes in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation Treated with Palifermin to Prevent Oral Mucositis.
Stiff PJ; Leinonen M; Kullenberg T; Rudebeck M; de Chateau M; Spielberger R
Biol Blood Marrow Transplant; 2016 Jan; 22(1):164-9. PubMed ID: 26303102
[TBL] [Abstract][Full Text] [Related]
35. [New drugs; palifermin].
Cohen AF; Dubois EA; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Dec; 150(50):2753-4. PubMed ID: 17225787
[TBL] [Abstract][Full Text] [Related]
36. Flexural cutaneous eruption due to palifermin.
Diaz Ley B; Guhl G; Eguren Michelena C; Fernandez Herrera J; Fraga J; Garcia Diez A
Br J Haematol; 2008 Feb; 140(4):464-5. PubMed ID: 18162122
[No Abstract] [Full Text] [Related]
37. Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
Yageman LA; Cronin SM; Peres E; Abidi MH; Ibrahim RB
J Oncol Pharm Pract; 2006 Jun; 12(2):119-21. PubMed ID: 16984751
[TBL] [Abstract][Full Text] [Related]
38. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience.
Wasko-Grabowska A; Rzepecki P; Oborska S; Barzal J; Mlot B; Gawronski K; Wasko M; Szczylik C
J BUON; 2012; 17(2):363-8. PubMed ID: 22740219
[TBL] [Abstract][Full Text] [Related]
39. Palifermin and chemotherapy-induced oral mucositis.
Köstler WJ; Hejna M; Zielinski CC
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791702
[No Abstract] [Full Text] [Related]
40. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy.
Coutsouvelis J; Corallo C; Spencer A; Avery S; Dooley M; Kirkpatrick CM
Crit Rev Oncol Hematol; 2022 Apr; 172():103606. PubMed ID: 35101586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
